<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypermethylation of several genes with various functions is frequent in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and has led to the use of demethylating agents in clinical trials </plain></SENT>
<SENT sid="1" pm="."><plain>The mechanism of hypermethylation remains unclear, limiting the development of new drugs </plain></SENT>
<SENT sid="2" pm="."><plain>Hopfer et al. investigated the role of DNA methyltransferases (DNMTs) during in vitro <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> hematopoietic cell differentiation </plain></SENT>
<SENT sid="3" pm="."><plain>They found that different subtypes of DNMTs were associated with different lineages in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and also during <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis, suggesting that DNMTs contribute to aberrant methylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> but are not the cause of this phenomenon </plain></SENT>
</text></document>